April 26th
Genomics Workshop
Genomic and Translational Science
in Hematologic Diseases
- Maher Albitar, M.D., CEO/CMO, Genomic Testing Cooperative, USA.
- Andre Goy, M.D., Physician in Chief, Hackensack Meridian Health, USA.
- Hong Zhong, Ph. D., Professor of Computer Science, Georgia Southern University, USA.
- Lacey Williams, M.D., Georgetown University, USA.
- Andrew Tiu M.D., Georgetown University, USA.
- Anne Renteria, M.D., Georgetown University School of Medicine, USA.
- Paul Sackstein, M.D., Georgetown University, USA.
- Sergio Rutella, M.D., Ph.D., FRCPath (Hematology). Nottingham Trent University, Nottingham, United Kingdom
- Ann-Kathrin Eisfeld, M.D., Ohio State University , USA.
- Lea Cunnigham, M.D., National Cancer Institute, NIH, USA.
- Gustavo Rivero, M.D., Georgetown University, USA.
- Joseph Roswarski, M.D., Georgetown University, USA.
- Kimberly Doucette, M.D. Georgetown University, USA.
7-8: Breakfast
8-8:10: Welcoming remarks
8:10-8:30: Clinical Applications of NGS (Albitar)
8:30-8:50: Artificial Intelligence in the clinical application of NGS data (Zhong)
8:50-9:10: Ex-vivo transcript deregulation in hemopoietic stem cell vs progenitors: Advancing Next Generation Sequencing Applicability– Tiphaine C. Martin. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York.
9:10-9:40:
“The immune landscape of P53 Acute Myelogenous Leukemia”
Sergio Rutella, M.D.,Ph.D., FRCPath (Hematology)
Director of the John van Gest Cancer Research Centre
Nottingham Trent University, Clifton, UK
9:40-10:00: Clinical applications of NGS in Myeloid Malignancies (Ann-Kathrin Eisfeld), Ohio State University
10:00-10:20: NGS in AML (Albitar and Lacey Williams)
10:20-10:40: NGS in MDS and MPN (Albitar and Andrew Tiu)
10:40-10:50: Break
10:50-11:10: Germline Predisposition Syndromes (Lea Cunnigham), The Role for BMT. National Institute of Health
11:10-11:30: NGS and Measurable Residual Disease (MRD) (Anne Renteria) Lombardi Cancer Institute, Georgetown University
11:30-11:50: Could NGS Guide GVHD prophylaxis?
11:50-12:20: Integrating NGS and Donor/Recipient Chimerism to Inform Relapse Risk and Post BMT Complications.
(Renteria, Olga Timofeva, Ala Ali, Albitar).
12:20 pm – 1:30 pm
1:30-1:50: Lymphoma treatment decisions based on molecular data (Goy) Hackensack Meridian Health
1:50-2:10: Lymphoma diagnosis using NGS data and artificial Intelligence (Maher Albitar)
2:10-2:30: Molecular monitoring of lymphoma (Kieron Dunleavy) Lombardi Cancer Institute, Georgetown University
2:30-2:50: Case presentation (Andre Goy and Maher Albitar)
3:00-3:20- Myeloma Molecular Diagnosis and Risk Stratification (Doucette)
3:20-3:30- Myeloma advances by using NGS data and artificial Intelligence (Albitar)
3:30-4:00- Case presentation (Doucette and Albitar).
April 27th
6th Myeloid Malignancies Symposium
Genomic and Clinical Science
in Hematologic Diseases
- Sidd Jaiswal, MD, Ph.D, BS,
Stanford Medicine Children’s Health, California, USA - Alvin Makohon-Moore M.D., Ph.D.,
Center for Discovery and Innovation- Hackensack University, New Jersey, USA - Kathy McGraw Ph.D.,
Myeloid Malignancies Program, National Cancer Institute, NIH, USA - Maher Albitar, M.D.,
Genomic Testing Cooperative, CEO, CMO., Irvine, California, USA - David Sallman, M.D.,
Lee Moffit Cancer Center, Tampa Florida - Hetty Carraway, MD, MBA
Cleveland Clinic, OH, USA - Amy DeZern M.D.,
Johns Hopkins University, MD, USA - James McClosky, M.D.,
Hackensack University Medical Center, USA - Farhad Ravandi, M.D.,
The University of Texas MD Anderson Cancer Center, Texas, USA - Romina Sosa, MD, Ph.D,
Fox Chase Cancer Center, Philadelphia, USA - Pedro Alcedo, M.D.,
Georgetown University School of Medicine, USA - Sergio Rutella, MD,
John Van Geest Cancer Research
Centre, Nottingham Trent University, Nottingham, United Kingdom - Mohamad Mohty MD,
Hematology and Cellular Therapy Department, Hôpital Saint-Antoine, and Université Pierre & Marie Curie, Paris, France - Keyzner Alla, M.D.,
Icahn School of Medicine at Mount Sinai, New York, USA - Saar I Gill, M.D., Ph.D.,
Perelman School of Medicine University of Pennsylvania - Nirali Shah, M.D.,
Pediatric Oncology Branch National Cancer Institute, NIH
8-8:05 am: Welcome
Chair and Section Moderators
Molecular Basis of Clonal Hematopoiesis
“From Clinical Observations to Bench”
Section moderator: Sidd Jaiswal, M.D., Ph.D., BS.,
Stanford Medicine Children’s Health, California, USA
8:05- 8:25 am Featured Lecture: “Leveraging to understand myeloid mutation fitness.”
Speaker: Sidd Jaiswal, M.D., Ph.D.,
Stanford Medicine Children’s Health, California, USA
8:25-8:45am “Feature Lecture: “The Theorem of Clonal Evolution Under Selective Pressure”
Speaker: Alvin Makohon-Moore M.D., Ph.D.,
Center for Discovery and Innovation- Hackensack University, New Jersey, USA
8:45-9:05am
“Mid-Atlantic Clonal Hematopoiesis Tumor Board”
Case and Precision Medicine Discussion (Moderator: Gustavo Rivero, M.D.,)
Alvin Makohon-Moore M.D., Ph.D., Center for Discovery and Innovation- Hackensack University, New Jersey, USA
Sidd Jaiswal, M.D. Stanford Medicine Children’s Health, California, USA
Kathy McGraw Ph.D., Myeloid Malignancies Program, National Cancer Institute, NIH, USA
Maher Albitar, M.D., Genomic Testing Cooperative, CEO, CMO., Irvine, California, USA |
Myelodysplasia
Section Moderator: David Salman, M.D.
Lee Moffit Cancer Center, Tampa Florida
9:05-9:25 am The gene regulatory basis of Myelodysplastic Syndrome
Speaker: Kathy McGraw Ph.D.,
Myeloid Malignancies Program, National Cancer Institute, NIH, USA
9:25-9:45 am What is the translational horizon of Myelodysplastic Syndrome Therapy?
Speaker: David Sallman, M.D.,
Lee Moffit Cancer Center, Tampa Florida
9:45-10:05 am Innovative approach for management of hypomethylating agent failure
Speaker: Hetty Carraway, M.D., MBA.
Cleveland Clinic, OH, USA
10:05-10:25am Novel therapies for Myelodysplastic Syndrome
Speaker: Amy DeZern M.D.,
Johns Hopkins University, MD, USA
Acute Myelogenous Leukemia
Section Moderator: Gustavo Rivero, M.D.,
Georgetown University School of Medicine
10:30-10:50 am 14 vs 21 vs 28 days for BCL2 inhibition in AML- what is best
Speaker: Naseema Gangat M.D., M.B.B.S.,
Division of Oncology Research, Mayo Clinic, Rochester, MN, USA
10:50-11:10 am Liposomal cytarabine/Daunorubicin vs HMA+ Venetoclax
“How to decide”
Speaker: James McClosky, M.D.,
Hackensack University Medical Center, USA
11:10-11:35 am How to optimize your patient for allogeneic transplantation- “New evolving Measurable residual disease concepts”
Speaker: Farhad Ravandi, M.D.,
The University of Texas MD Anderson Cancer Center, Texas, USA
Noon Theater A
12:00- 1:00 pm
Novel Epigenetic Therapeutic for AML
Myeloproliferative Neoplasms
Section Moderator: Craig Kessler, M.D.,
Georgetown University School of Medicine
1:00-1:30 pm Advances in the therapy of Polycythemia Vera.
Speaker: Romina Sosa, M.D., Ph.D.,
Fox Chase Cancer Center, Philadelphia, USA
1:30-1:50 pm Novel JAK inhibitor therapies
Speaker: Pedro Alcedo, M.D.,
Georgetown University School of Medicine, USA.
Biologic and Cellular Therapy for Myeloid Disorder
Section Moderator: Anne Renteria, M.D.,
Georgetown University School of Medicine
2:00-2:30 pm Newer Bispecific Antibodies
Speaker: Sergio Rutella, M.D.,
John Van Geest Cancer Research
Centre, Nottingham Trent University, Nottingham, United Kingdom
2:30-3:00 pm Haplo vs MUD donor transplantation for high-risk AML?
Speaker Mohamad Mohty M.D.,
Hematology and Cellular Therapy Department, Hôpital Saint-Antoine, and Université Pierre & Marie Curie, Paris, France
3:05-3:25 pm How to Optimize your Patients with Myelofibrosis for Transplant?Speaker: Keyzner Alla, M.D.,
Icahn School of Medicine at Mount Sinai, New York, USA
3:30-3:55 pm Advances in CART for AML
Speaker: Saar I Gill, M.D., Ph.D.,
Perelman School of Medicine University of Pennsylvania
3:55- 4:20 pm Innovative Cell Therapy Trials
Speaker: Nirali Shah, M.D.,
Pediatric Oncology Branch National Cancer Institute, NIH
4:25-4:30 pm Abstracts Awards
4:30-4:35 pm Announcement –MyeloHub Genomic Consortium
[Georgetown University-Hackensack University and Baylor College of Medicine]
4:35-4:40 pm Final Remarks – 2025 Event Promotion –
